References
Key articles
Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.Full text Abstract
Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.Full text Abstract
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: thyroid carcinoma. 2019 [internet publication].Full text
Reference articles
1. Gimm O. Thyroid cancer. Cancer Lett. 2001 Feb 26;163(2):143-56. Abstract
2. Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.Full text Abstract
3. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998 Dec 15;83(12):2638-48.Full text Abstract
4. Bertagna F, Treglia G, Piccardo A, et al. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012 Nov;97(11):3866-75. Abstract
5. Phillips JS, Pledger DR, Hilger AW. Rapid thyrotoxicosis in anaplastic thyroid carcinoma. J Laryngol Otol. 2007 Jul;121(7):695-7. Abstract
6. National Cancer Institute. Cancer stat facts: thyroid cancer. Surveillance, Epidemiology, and End Results (SEER) Program. [internet publication]Full text
7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.Full text Abstract
8. James BC, Mitchell JM, Jeon HD, et al. An update in international trends in incidence rates of thyroid cancer, 1973-2007. Cancer Causes Control. 2018 May;29(4-5):465-73.Full text Abstract
9. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-336.Full text Abstract
10. Grinspoon S, Seely E, eds. 3 perspectives on thyroid cancer: what's new in treatment and research. Endocr News. 2005;30:10-15.
11. Kim TH, Park YJ, Lim JA. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012 Apr 1;118(7):1764-73.Full text Abstract
12. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.Full text Abstract
13. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol. 2003 Aug;12(2):69-90. Abstract
14. Patel KN, Singh B. Genetic considerations in thyroid cancer. Cancer Control. 2006 Apr;13(2):111-8. Abstract
15. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):775-82. Abstract
16. Sherman SI. Thyroid carcinoma. Lancet. 2003 Feb 8;361(9356):501-11. Abstract
17. Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009 Oct;89(5):1193-204.Full text Abstract
18. Spallek L, Krille L, Reiners C, et al. Adverse effects of iodine thyroid blocking: a systematic review. Radiat Protn Dosimetry. 2012 Jul;150(3):267-77. Abstract
19. American College of Radiology. ACR-AIUM-SPR-SRU practice parameter for the performance and interpretation of diagnostic ultrasound of the extracranial head and neck. 2018 [internet publication].Full text
20. Novoa E, Gürtler N, Arnoux A, et al. Role of ultrasound-guided core-needle biopsy in the assessment of head and neck lesions: a meta-analysis and systematic review of the literature. Head Neck. 2012 Oct;34(10):1497-503. Abstract
21. Webb RC, Howard RS, Stojadinovic A, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63. Abstract
22. Sebag F, Vaillant-Lombard J, Berbis J, et al. Shear wave elastography: a new ultrasound imaging mode for the differential diagnosis of benign and malignant thyroid nodules. J Clin Endocrinol Metab. 2010 Dec;95(12):5281-8. Abstract
23. Rago T, Scutari M, Santini F, et al. Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology. J Clin Endocrinol Metab. 2010 Dec;95(12):5274-80. Abstract
24. Wu LM, Gu HY, Qu XH, et al. The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis. Eur J Radiol. 2012 Aug;81(8):1798-805. Abstract
25. Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol. 2019 Jul;72(7):460-7.Full text Abstract
26. Mekel M, Nucera C, Hodin RA, et al. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010 Jul;200(1):136-43. Abstract
27. Hegedus L. Can elastography stretch our understanding of thyroid histomorphology? J Clin Endocrinol Metab. 2010 Dec;95(12):5213-5. Abstract
28. Hershman JM, Cheng S, Gianoukakis, et al. Update in thyroidology. 2010. J Clin Endocrinol Metab. 2011 Jan;96(1):9-14. Abstract
29. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77.Full text Abstract
30. Balasubramanian SP, Harrison BJ. Systematic review and meta-analysis of sentinel node biopsy in thyroid cancer. Br J Surg. 2011 Mar;98(3):334-44. Abstract
31. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.Full text Abstract
32. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11):1104-39.Full text Abstract
33. Shaha AR. Advances in the management of thyroid cancer. Int J Surg. 2005;3(3):213-20. Abstract
34. Lang BH, Lo CY, Chan WF, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007 Mar;245(3):366-78. Abstract
35. Lang BH, Lo CY, Chan WF, et al. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer. 2007 Mar;14(1):29-42. Abstract
36. US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017 May 9;317(18):1882-1887.Full text Abstract
37. Perros P, Boelaert K, Colley S, et al; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122.Full text Abstract
38. Expert Panel on Neurological Imaging:., Hoang JK, Oldan JD, et al. ACR Appropriateness Criteria: thyroid disease. J Am Coll Radiol. 2019 May;16(5s):S300-S314.Full text Abstract
39. Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.Full text Abstract
40. Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii110-vii119.Full text Abstract
41. Cobin RH, Gharib H, Bergman DA, et al; Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001 May-Jun;7(3):202-20.Full text Abstract
42. White ML, Gauger PG, Doherty GM, et al. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007 May;31(5):895-904. Abstract
43. Shan CX, Zhang W, Jiang DZ, et al. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope. 2012 Apr;122(4):797-804. Abstract
44. Zetoune T, Keutgen X, Buitrago D, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010 Dec;17(12):3287-93. Abstract
45. Hughes DT, Doherty GM. Central neck dissection for papillary thyroid cancer. Cancer Control. 2011 Apr;18(2):83-8. Abstract
46. Samraj K, Gurusamy KS. Wound drains following thyroid surgery. Cochrane Database Syst Rev. 2007;(4):CD006099. Abstract
47. Inabnet WB. Surgical management of thyroid cancer. Endocr Pract. 2000 Nov-Dec;6(6):465-8. Abstract
48. Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012 Mar;33(3):275-82. Abstract
49. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New Engl J Med. 2012 May 3;366(18):1674-85.Full text Abstract
50. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011 Dec;150(6):1250-7. Abstract
51. Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186-193. Abstract
52. Brose MS, Nutting CM, Jarzab B, et al; DECISION Investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26;384(9940):319-28.Full text Abstract
53. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30.Full text Abstract
54. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41.Full text Abstract
55. Frampton JE. Vandetanib: in medullary thyroid cancer. Drugs. 2012 Jul 9;72(10):1423-36. Abstract
56. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-141.Full text Abstract
57. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.Full text Abstract
58. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11):1104-39.Full text Abstract
59. Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. Abstract
60. Ball DW. Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab. 2010 Jan;95(1):60-1. Abstract
61. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46.Full text Abstract
62. Tappenden P, Carroll C, Hamilton J, et al. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health Technol Assess. 2019 Feb;23(8):1-144.Full text Abstract
63. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13.Full text Abstract
64. US Food and Drug Administration. FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. Nov 2018 [internet publication].Full text
65. Bhangoo MS, Sigal D. TRK Inhibitors: Clinical Development of Larotrectinib. Curr Oncol Rep. 2019 Feb 4;21(2):14.Full text Abstract
66. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 Feb 22;378(8):731-9.Full text Abstract
67. Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018 May;19(5):705-14.Full text Abstract
68. Fan LJ, Jiang J. Present and future of robot-assisted endoscopic thyroid surgery. Chin Med J (Engl). 2012 Mar;125(5):926-31. Abstract
69. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: thyroid carcinoma. 2019 [internet publication].Full text
70. Francis GL, Waguespack SG, Bauer AJ, et al; The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul;25(7):716-59.Full text Abstract
71. Alberta Clinical Practice Guidelines. Investigation and management of primary thyroid dysfunction. Apr 2014 [internet publication].Full text
72. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11):1104-39.Full text Abstract
73. American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011 Apr;21(4):335-46.Full text Abstract
74. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Dec 1;30(12):1856-83.Full text Abstract
75. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol. 2002 Jul;3(7):407-14. Abstract
76. Widder S, Pasieka JL. Primary thyroid lymphomas. Curr Treat Options Oncol. 2004 Aug;5(4):307-13. Abstract
77. Corrigan KL, Williamson H, Elliott Range D, et al. Treatment Outcomes in Anaplastic Thyroid Cancer. J Thyroid Res. 2019;2019:8218949.Full text Abstract
78. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med. 2001 Aug 16;345(7):512-6. Abstract
79. Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. J Clin Oncol. 2018 Jun 20;36(18):1831-1839.Full text Abstract
80. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 Oct 1;117(19):4439-46.Full text Abstract
81. Genton CY, Dutoit M, Portmann L, et al. Pathologic fracture of the femur neck as first manifestation of a minute columnar cell carcinoma of the thyroid gland. Pathol Res Pract. 1998;194(12):861-3 Abstract
82. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar;91(3):878-84. Abstract
83. Yoo J, Cosby R, Driedger A. Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review. Curr Oncol. 1991 Jan;11(1):401-11. Abstract
84. Ma C, Xie J, Liu W, Wang G, et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev. 2010;(11):CD008302. Abstract
85. Royal College of Physicians (UK). Evidence-based indications for the use of PET-CT in the UK 2016. May 2016. [internet publication].Full text
Use of this content is subject to our disclaimer